Riboflavin Corneal Crosslinking for Brittle Cornea Syndrome and Ehlers-Danlos Syndrome Type VI

Sponsor
Hadassah Medical Organization (Other)
Overall Status
Unknown status
CT.gov ID
NCT01307527
Collaborator
(none)
1
1

Study Details

Study Description

Brief Summary

Brittle Cornea Syndrome and Ehlers-Danlos Syndrome (EDS) type VI are rare collagen-connective tissue disorders that predispose affected individuals to the development of perforated corneas from the mildest of eye trauma or even spontaneously. Clinical studies evaluating riboflavin-corneal crosslinking have found that it dramatically increases corneal rigidity. Given the success and safety of riboflavin crosslinking, the investigators believe that it can increase the corneal stability in patients affected these disseases, preventing perforation. It is furthermore possible, that riboflavin crosslinking will allow corneal transplants to successfully be performed on blind eyes that have already perforated and opacified. The purpose of the study is to determine whether corneal crosslinking can be safely performed on individuals with Brittle Cornea Syndrome or Ehlers-Danlos Syndrome type VI.

Condition or Disease Intervention/Treatment Phase
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
1 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention

Outcome Measures

Primary Outcome Measures

  1. Adverse Events from Cornea Riboflavin Crosslinking in Brittle Cornea Syndrome or Ehlers Danlos Type VI [3 Months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
Adult Patient with:
  1. Genetic diagnosis of either Brittle Cornea Syndrome or EDS-VI, and

  2. Either:

  • Personal History of either spontaneous corneal perforation or corneal perforation due to minor ocular mechanical trauma or

  • Immediate family member with history of either spontaneous corneal perforation or corneal perforation due to minor ocular mechanical trauma

Exclusion Criteria:
  • Any patient that is deemed to be unable to fully cooperate during the crosslinking procedure

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hadassah Medical Organization Jerusalem Israel

Sponsors and Collaborators

  • Hadassah Medical Organization

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT01307527
Other Study ID Numbers:
  • BTL-CXL-HMO-CTIL
First Posted:
Mar 3, 2011
Last Update Posted:
Mar 3, 2011
Last Verified:
Feb 1, 2011

Study Results

No Results Posted as of Mar 3, 2011